New weapon against cancer: early trial tests antibody to boost immune attack
NCT ID NCT06932952
Summary
This is an early-stage trial testing a new antibody drug called BYON4228, both alone and combined with an existing immunotherapy (pembrolizumab), for people with advanced solid tumors. The main goals are to find a safe dose and see how the body processes the drug. It is for patients whose cancer has progressed after standard treatments or for whom no standard options exist.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CIOCC Hospital Universitario HM Sanchinarro
Madrid, Spain
-
Hospital Universitario Fundación Jiménez Díaz
Madrid, Spain
-
Institut Jules Bordet
Brussels, Belgium
-
The Christie NHS Foundation Trust
Manchester, United Kingdom
-
The Royal Marsden
Sutton, United Kingdom
-
UZ Leuven
Leuven, Belgium
Conditions
Explore the condition pages connected to this study.